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Abstract
Background: Gastrointestinal cancer, such as gastric, colon and rectal cancer, is a major medical and
economic burden worldwide. However, the exact mechanism of gastrointestinal cancer development still
remains unclear. RAS genes have been elucidated as major participants in the development and progression
of a series of human tumours and the single nucleotide polymorphism at H-RAS cDNA position 81 was
demonstrated to contribute to the risks of bladder, oral and thyroid carcinoma. Therefore, we
hypothesized that this polymorphisms in H-RAS could influence susceptibility to gastrointestinal cancer as
well, and we conducted this study to test the hypothesis in Chinese population.
Methods: A population based case-control study, including 296 cases with gastrointestinal cancer and 448
healthy controls selected from a Chinese population was conducted. H-RAS T81C polymorphism was
genotyped by Polymerase Chain Reaction-Restriction Fragment Length Polymorphism (PCR-RFLP) assay.
Results: In the healthy controls, the TT, TC and CC genotypes frequencies of H-RAS T81C polymorphism,
were 79.24%, 19.87% and 0.89%, respectively, and the C allele frequency was 10.83%. Compared with TT
genotype, the TC genotype was significantly associated with an increased risk of gastric cancer (adjusted
OR = 3.67, 95%CI = 2.21–6.08), while the CC genotype showed an increased risk as well (adjusted OR =
3.29, 95%CI = 0.54–19.86), but it was not statistically significant. In contrast, the frequency of TC genotype
was not significantly increased in colon cancer and rectal cancer patients. Further analysis was performed
by combining TC and CC genotypes compared against TT genotype. As a result, a statistically significant
risk with adjusted OR of 3.65 (95%CI, 2.22–6.00) was found in gastric cancer, while no significant
association of H-RAS T81C polymorphism with colon cancer and rectal cancer was observed.
Conclusion: These findings indicate, for the first time, that there is an H-RAS T81C polymorphism existing
in Chinese population, and this SNP might be a low penetrance gene predisposition factor for gastric
cancer.
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Background
Gastrointestinal cancer, including cancers of the oesopha-
gus, stomach, small intestine, colon, rectum and liver etc,
is a major medical and economic burden worldwide.
Although the incidence and mortality of gastrointestinal
cancer has been gradually decreasing for decades, some
common types of gastrointestinal cancer are steadily in
the top five leading cause of new cancer cases and deaths,
such as gastric cancer, colon and rectal cancer[1]. Multiple
factors have been proposed to play important roles in
human carcinogenesis, however, the exact mechanism of
gastrointestinal cancer development still remains unclear.
Mammalian cells contain three functional RAS  proto-
oncogenes, known as H-RAS, K-RAS, and N-RAS, which
encode small GTP-binding proteins in terms of p21rass.
The RAS proteins are GTPases that bind to GTP and GDP
nucleotides[2]. The switch between their inactive (GDP-
bound) and active (GTP-bound) forms, together with
their ability to bind to target proteins, provides the mech-
anism for the downstream transmission of the cellular sig-
nals. Their natural role is to relay extracellularly derived
signals to a number of pathways controlling cellular pro-
liferation and differentiation[3]. RAS genes have been elu-
cidated as major participants in the development and
progression of a series of human tumours, such as gas-
trointestinal cancer, lung cancer and breast cancer. It was
reported that just one point mutation occurring in
codon12, 13 or 61 could result in continuous stimulation
of cell proliferation or, alternatively, a 5- to 50-fold ampli-
fication of the wild type gene[4]. As a result, the codon12,
13 and 61 are also called mutation hotpots. Numerous
epidemiological studies on pancreatic, gastric, colorectal
and non-small cell lung cancer evaluate the potential role
of these mutation hotspots, but the results are still con-
flicting up to now [5-8].
Besides the mutation hotspots of H-RAS  mentioned
above, another single nucleotide polymorphism at H-RAS
cDNA position 81 T→C (rs12628), primarily found by
Taparowsky et al in 1982[9], was shown to be associated
with the risk of human cancers as well. Johne's research
indicated that the individuals harbouring the
homozygous C-genotype of the H-RAS T81C were at an
increased risk of bladder cancer [10]. More recently, it was
demonstrated that the variant C allele of this genetic pol-
ymorphism could increase the risk of oral carcinoma, par-
ticularly in male population[11]. However, the number of
studies conducted to examine the H-RAS T81C polymor-
phism is not sufficient; moreover, the results of them are
controversial yet. Especially, there is a lack of investigation
on gastrointestinal cancer, such as gastric, colon and rectal
cancer.
Therefore, in the present research, we hypothesize that the
H-RAS T81C polymorphism may have an effect on the H-
RAS expression and activity, and ultimately may play a
role in modulating the susceptibility to gastrointestinal
cancer. In order to verify our hypothesis, a population
based case-control study was conducted to investigate the
association between the H-RAS T81C genotypes and the
risk of gastrointestinal cancer in Chinese population. In
addition, a meta-analysis was performed to estimate the
risk of H-RAS T81C polymorphism for cancers.
Methods
Study subjects
This population-base case-control study included 296 gas-
trointestinal cancer patients and 448 healthy controls,
and the details of the study population had been
described previously[12,13]. In brief, the registry informa-
tion of this population was initially collected for a cohort
study on colorectal cancer in 1989 in Jiashan County,
Zhejiang Province, China. Meanwhile a cancer surveil-
lance and registry system covering the whole county was
established for reporting new cancer patients of colorectal
cancer and all other kinds of cancers. There were no age,
gender, or stage restrictions, but patients with other malig-
nant disease in their medical history were excluded. 296
eligible patients with histologically confirmed gastric can-
cer, colon cancer or rectal cancer reported by the cancer
registry system were included as cases in the study. Gastric
cancer patients consisted of 64 males and 26 females from
45 to 78 years old, while colon and rectal cancer patients
consisted of 105 males and 101 females from 35 to 81
years old. Simultaneously, 448 population controls who
did not have a history of cancer were selected randomly
and recruited from all permanent residents listed in the
cancer registry system during the same period. All the par-
ticipants were ethnic Han Chinese residents in Jiashan
County.
At the beginning of investigation, written informed con-
sent was obtained from each participant, and then they
were face-to-face interviewed by professionally trained
interviewers using a structured questionnaire, including
demographic characteristics, personal habits (cigarette
smoking, alcohol drinking, etc) and health factors (family
history of cancer at any site including all first- and second-
degree relatives of both genders, medical and dietary his-
tory, etc). Individuals who smoked ≥1 cigarette per day for
over 1 year were defined as smokers, and those consumed
≥1 alcohol drinks per day for over 3 months were consid-
ered as drinkers. In addition, a 2 ml venous blood sample
was drawn from each subject with the permission and
saved in vacuum tube containing sodium citrate anticoag-
ulation. This study was performed with the approval of
the Medical Ethical Committee of Zhejiang UniversityBMC Cancer 2008, 8:256 http://www.biomedcentral.com/1471-2407/8/256
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School of Medicine. The blood samples were stored at -
60°C ultra low temperature freezers for DNA isolation.
H-RAS T81C genotyping
The genomic DNA was extracted from peripheral blood
samples using modified salting-out procedure as previ-
ously reported[14]. The DNA concentration and purity
was measured using BioPhotometer (Eppendorf, Ham-
burg, Germany) at 260 nm.
For determination of the H-RAS genetic polymorphism 81
T→C, Polymerase Chain Reaction – Restriction Fragment
Length Polymorphism (PCR-RFLP) assay was performed
at the Molecular Epidemiology Laboratory in the Zhejiang
University School of Medicine. The sequence of the oligo-
nucleotide primers and the conditions for PCR amplifica-
tion were reported elsewhere[10]. A 200 bp DNA segment
was amplified using forward primer 5'-CTTGGCAGGT-
GGGGCAGGAGA-3' and reverse primer 5'-GGCACCT-
GGACGGCGGCGCTAG-3'. The PCR mixture (20 μl)
contained 2 μl of 10 × PCR buffer, 2 μl of deoxyribonucle-
otide triphosphates (dNTPs, 2 mM each), 1.6 μl MgCl2
(25 mM each), 0.2 μl of each primer (10 μM each), 0.5 μl
genomic DNA (~50 ng) and 0.5 Unit of Taq  DNA
polymerase (Sangon, Shanghai, China). After 5 min of
initial denaturation at 94°C in PTC-200 thermal cycler
(BioRad, USA), the prepared PCR mixtures were subjected
to 35 cycles of denaturation for 30 s at 94°C, annealing
for 30 s at 50°C and extension for 30 s at 72°C. A final
extension period of 5 min at 72°C was performed to com-
pleted the reaction. Subsequently, 6 μl of amplified prod-
uct was added with 1 μl of 10× digestion buffer containing
3 units DraIII (New England Biolabs, Schwalbach, Ger-
many). After 6 hours digestion at 37°C, the products were
separated by electrophoresis on a 2% agarose gel stained
with ethidium bromide and observed on an ultraviolet
fluorescence imaging system. The CC homozygote with
DraIII restriction site was cut into fragments of 145 bp and
55 bp, while the 81TT homozygote presented a single frag-
ment of 200 bp. About 10% of the samples were selected
randomly to be identified repeatedly for accuracy, and the
results were 100% concordant. The genotype assay
described above was done with case/control status
blinded to the laboratory technician.
Statistical analysis
Pearson's χ2 test was used for comparing the distributions
of the demographic characteristics, personal habits such
as cigarette smoking and alcohol drinking etc, and the dis-
tribution of H-RAS  T81C allele types and genotypes
between cases and controls. Hardy-Weinberg equilibrium
was tested by a goodness-of-fit χ2 test to compare the
observed genotype frequencies within the case-control
groups to the anticipated genotype frequencies calculated
from the observed allele frequencies. Unconditional logis-
tic regression analysis was performed to calculate the odds
ratios (ORs) with 95% confidence intervals (95% CIs) for
estimating the association between certain genotype and
cancers with adjustment for potential confounding fac-
tors, including age (as a continuous variable), gender,
smoking, drinking and family history of cancer (as dichot-
omous variables). H-RAS T81C polymorphism was ana-
lyzed as dichotomized variable using TT genotype as the
reference category. Stratified analyses were used to explore
potential gene-environment interactions. A p value of less
than 0.05 indicated statistical significance. In the meta-
analysis, raw data for genotype frequencies, without
adjustment, were used for calculation of the estimates of
OR. The extent of heterogeneity was examined by the
Cochran's χ2 test. The statistical analyses were performed
with Statistical Analysis System software version 8.0 (SAS
Institute, Cary, NC) and the meta-analysis was carried out
using RevMan software version 4.2.
Results
The demographic characteristics and personal habits of
the study subjects were summarized in Table 1. There was
no significant difference in gender, age, family history of
cancer, smoking and drinking status among colon can-
cers, rectal cancers and healthy controls. Otherwise, the
age, gender and smoking status were significantly differ-
ent between gastric cancers and controls.
The observed genotype distributions of H-RAS  T81C
among cases and controls were shown in Table 1 as well.
In healthy controls, the frequencies of TT, TC and CC gen-
otypes were 79.24%, 19.87% and 0.89%, which did not
deviate from the Hardy-Weinberg equilibrium (χ2  =
0.375, p = 0.541), while those frequencies were 53.33%,
44.44% and 2.22% in gastric cancer patients, respectively.
The frequency of C allele observed in gastric cancers was
about 24.44% which was significantly higher than that in
controls 10.83% (χ2 = 24.413, p < 0.0001). Meanwhile,
the frequencies of C allele in colon cancer and rectal can-
cer, 12.90% and 12.39% respectively, were also higher
than that in controls. However, no significant difference
in genotype or allele distribution was found among colon
cancer, rectal cancer and controls (data not shown).
Furthermore, crude ORs and adjusted ORs were calculated
to evaluate the risk of gastrointestinal cancer. Compared
with TT genotype, the TC genotype was significantly asso-
ciated with a increased risk of gastric cancer (crude OR =
3.32, 95%CI = 2.06–5.37, p < 0.0001), and the CC geno-
type with more risk, crude OR was 3.69, but it was not sta-
tistically significant, this may be due to limited number of
CC genotype carriers. The same results were observed after
adjustment (shown in Table 2). In contrast, the TC geno-
type was not significantly increased in colon cancer and
rectal cancer patients. Since H-RAS is one of proto-onco-BMC Cancer 2008, 8:256 http://www.biomedcentral.com/1471-2407/8/256
Page 4 of 7
(page number not for citation purposes)
gene, mutation of which could confer a dominant nega-
tive phenotype, and the frequency of the CC genotype is
very low (<0.05), further analysis was performed by com-
bining TC and CC genotypes compared against TT geno-
type. As a result, a statistically significant risk with
adjusted OR of 3.65 (95%CI, 2.22–6.00, p < 0.0001) was
found in gastric cancer, while no significant association of
H-RAS T81C polymorphism with colon cancer and rectal
cancer was observed. In addition, the effect of H-RAS
T81C polymorphism was further examined by stratifica-
tion of age, gender, family history, smoking and drinking
status. However, no significant gene-environment interac-
tion in relation to gastric cancer, colon cancer and rectal
cancer was found (data not shown).
Three other studies on H-RAS T81C polymorphism and
cancer risk were available in the literature including blad-
der, thyroid and oral cancer patients. Because of the small
sample size of these studies, we carried out a meta-analy-
sis to obtain an overall assessment of the effects of the H-
RAS T81C polymorphism on human cancers, which was
examined according to H-RAS genotype in all published
studies and in our patients. As presented in Fig. 1, the test
for heterogeneity was not significant (χ2 = 9.87, p = 0.02),
Table 1: Distribution of selected characteristics in the study subjects
Cases
No.(%)
Controls
No.(%)
Gastrointestinal cancer Gastric cancer Colon cancer Rectal cancer
No. of subjects 296 90 93 103 448
Gender
Male 169(57.09) 64(71.11) 48(51.61) 57(50.44) 223(49.78)
Female 127(42.91) 26(28. 89) 45(48.39) 56(49.56) 225(50.22)
Age
Mean ± SD 61.76 ± 9.92 64.68 ± 9.01 61.59 ± 8.87 59.57 ± 10.89 60.67 ± 10.92
Smoking
No 156(52.70) 33(36.67) 53(56.99) 70(61.95) 269(60.04)
Yes 140(47.30) 57(63.33) 40(43.01) 43(38.05) 179(39.96)
Drinking
No 202(68.24) 56(62.22) 65(69.89) 81(71.68) 322(71.88)
Yes 94(31.76) 34(37.78) 28(30.11) 32(28.32) 126(28.13)
Family history
No 212(71.62) 68(75.56) 68(73.12) 76(67.26) 338(75.45)
Yes 84(28.38) 22(24.44) 25(26.88) 37(32.74) 110(24.55)
H-RAS T81C
TT 204(68.92) 48(53.33) 71(76.34) 85(75.22) 355(79.24)
TC 88(29.73) 40(44.44) 20(21.51) 28(24.78) 89(19.87)
CC 4(1.35) 2(2.22) 2(2.15) 0(0.00) 4(0.89)
Allele frequencies
T 496(83.78) 136(75.56) 162(87.10) 198(87.61) 799(89.17)
C 96(16.22) 44(24.44) 24(12.90) 28(12.39) 97(10.83)
Table 2: H-RAS T81C polymorphism and gastrointestinal cancer risk
Genotype Gastrointestinal cancer Gastric cancer Colon cancer Rectal cancer
Crude OR
(95%CI)
Adjusted 
OR*
(95%CI)
Crude OR
(95%CI)
Adjusted 
OR
(95%CI)
Crude OR
(95%CI)
Adjusted 
OR
(95%CI)
Crude OR
(95%CI)
Adjusted 
OR
(95%CI)
TT 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00
TC 1.72
(1.22, 2.42)
1.74
(1.23, 2.46)
3.32
(2.06, 5.37)
3.67
(2.21, 6.08)
1.12
(0.65, 1.94)
1.15
(0.66, 1.99)
1.26
(0.76, 2.04)
1.25
(0.77, 2.04)
CC 1.74
(0.43, 7.03)
1.66
(0.41, 6.77)
3.69
(0.66, 20.73)
3.29
(0.54, 19.86)
2.50
(0.45, 13.91)
2.57
(0.46, 14.46)
--
TC+CC 1.72
(1.23, 2.41)
1.74
(1.24, 2.44)
3.34
(2.08, 5.36)
3.65
(2.22, 6.00)
1.18
(0.70, 2.01)
1.20
(0.71, 2.06)
1.26
(0.76, 2.04)
1.25
(0.77, 2.04)
*OR adjusted for age, gender, family history, status of cigarette smoking and alcohol drinkingBMC Cancer 2008, 8:256 http://www.biomedcentral.com/1471-2407/8/256
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suggesting that the random effect model could be used to
assess the odds ratio. The pooled odds ratio was 1.38
(95% CI, 1.01–1.98), which was significant.
Discussion
A multi-factorial model of human carcinogenesis is cur-
rently accepted, according to which different dietary and
non-dietary factors, including genetic susceptibility, are
involved at different stages in the cancer process[15]. RAS
gene, serving as molecular switches in pivotal processes
governing cellular growth and differentiation, have been
found to be amplified and over expressed in gastric carci-
nomas[16,17]. Several molecular alternations in RAS gene
have been identified such as minisatellites and mutations,
however, research on the single nucleotide polymorphism
in RAS gene was rare [18-20]. In the present study, analy-
ses of the polymorphism of H-RAS T81C in gastrointesti-
nal cancer patients were carried out compared with
healthy controls. The frequency of C allele in the Chinese
healthy population was 10.83%, which was lower than
that in Johne's study (26.42% in Germany)[10] and Sath-
yan's study (20.00% in India)[11]. This observation indi-
cates that the distribution of H-RAS T81C polymorphism
seems to be genetically different in various ethnics. In the
aforementioned study, they reported that H-RAS 81CC
homozygous genotype showed 2-fold risk of bladder can-
cer and oral cancer. In this study, a statistically significant
increased risk for gastric cancer was observed in the TC
and CC genotypes combination compared to the TT gen-
otype, and the adjusted OR achieved 3.65, which indi-
cated that H-RAS  T81C polymorphism is a strongly
susceptibility factor for the development of gastric cancer.
On the other hand, we did not find any association of H-
RAS T81C polymorphism with colon cancer and rectal
cancer, which derived from the same population.
However, this epidemiological study could not provide
the mechanism by which H-RAS  T81C polymorphism
modifies risk of different kinds of cancer. Although RAS
gene is ubiquitously expressed, the mRNA analysis reveals
different tissue expression levels suggesting that RAS fam-
ily members probably are expressed in a tissue specificity
fashion[3].  K-RAS  is mostly expressed in the pancreas,
colorectal and non-small cell lung cancer, while H-RAS is
common in squamous cell carcinomas, bladder carcino-
mas and renal cancers. K-RAS mutations have been found
in 15%–68% of sporadic colorectal cancer[21]. Keller et
al. reported that endogenous K-RAS resulted in the most
dramatic effect of the RAS  isoforms (K > H or N) in
human colorectal cancer cells[22]. However, K-RAS muta-
tions are rarely observed in gastric cancer[17,23,24] and
increased expression of the H-RAS oncogene product was
found in gastric cancer[25,26]. Consistent with the tissue
specificity hypothesis, our finding suggested that the H-
RAS gene played a more important role in gastric cancer
than in colorectal cancer. Although this polymorphism
does not lead to the alternation of RAS protein structure,
it affects the cancer susceptibility possibly through linkage
disequilibrium with other potential functional variant of
H-RAS. One of the linkage candidate is a region of varia-
ble tandem repeats about 1 kb downstream exon4, with a
possible transcriptional enhancer activity[27]. Another
associated polymorphic site is hexanucleotide repeat
located about 80 bp upstream of the 5'-end of exon1[28].
Recently, it is reported that H-RAS T81C might be serve as
a marker of other polymorphisms in intron D2 of H-RAS
that would act as regulators of IDX inclusion[29]. As it was
not examined in the present study, it would be interesting
to conduct more studies on the linkage of H-RAS T81C
polymorphism with the other candidate polymorphic
sites in order to reveal the underlying mechanism.
It has been suggested that sample size is always an issue of
concern in the case-control analysis and statistical power
of the analysis would generally increase with increasing
size of sample[30]. We only recruited 296 survival cases
and the sample size might not be large enough to detect
the low penetrance effect of the genes, especially for the
Meta-analysis of H-RAS T81C polymorphism for all cancers Figure 1
Meta-analysis of H-RAS T81C polymorphism for all cancers.
Study   Cases   Controls  OR  (random)  OR  (random)
 n/N   n/N  95%  CI  95%  CI
 Johne  A       161/312            196/360      0.89 [0.66, 1.21] 
 Castro  P        53/85              52/102      1.59 [0.89, 2.86] 
 Sathyan  KM        82/176             50/142      1.61 [1.02, 2.53] 
 This  study        92/296             93/448      1.72 [1.23, 2.41] 
Total (95% CI)  869                1052      1.38 [1.01, 1.98]
Total events: 388 (Cases), 391 (Controls) 
 0.1  0.2  0.5  1  2  5   10 BMC Cancer 2008, 8:256 http://www.biomedcentral.com/1471-2407/8/256
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SNPs with low frequency. Therefore, we pooled all pub-
lished data together with ours, and then performed a
meta-analysis to examine the association between the H-
RAS T81C polymorphism and the cancer risk. Overall, the
C allele carriers, including TC genotype and CC genotype
carriers, have a 38% increased risk of cancer. It is reasona-
ble to believe that the variant of H-RAS gene could be
associated with cancer risk, and it will be of interest in test
if this genetic polymorphism is associated with increased
risk of other malignant tumors.
Another limitation should be addressed in this study.
Helicobacter pylori infection has been defined as a crucial
risk factor for gastric cancer by numerous intensive
researches, which lead to an improved understanding of
the etiology and pathogenesis [31]. Unfortunately, infor-
mation of Helicobacter pylori infection in our study is not
available, as a result of that we can not analyze the inter-
action between H-RAS polymorphism and Hp infection
status.
Conclusion
In summary, this study provides the evidences that the
polymorphism of H-RAS T81C may be a risk factor for the
development of gastric cancer in a Chinese population.
Because this is the first study to report the significant asso-
ciation between H-RAS T81C polymorphism and gastric
cancer susceptibility, additional studies with large sample
size and detailed Hp infection information on gastric can-
cer are warranted in different ethnic populations to con-
firm our findings.
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